

...very early that the correspondence is  
being deposited with the United States  
Postal Service as first class mail in an  
envelope addressed to the Director of  
Patents and Trademarks, Washington, D.C. 20231, on

FELFE & LYNCH

OCT  
20  
1994

LUD 5253.3-JEL/NDH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Thierry Boon et al.  
Patent No. : 5,342,774  
Issued : August 30, 1994  
For : NUCLEOTIDE SEQUENCE ENCODING THE  
TUMOR REJECTION ANTIGEN PRECURSOR,  
MAGE-1

October 19, 1994

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

REQUEST FOR CERTIFICATE OF CORRECTION  
(37 C.F.R. § 1.323)

Sir:

Upon review, errors were found in the above-identified patent. One was caused by applicants' mistake. Pursuant to 37 C.F.R. §1.323 a check in the amount of \$100.00 (37 C.F.R. §1.20a), accompanies this request.

Column 5, line 23: change "P515A" to -- P815A -- (see page 12, line 2 of the specification).

Column 10, line 64: change "eDNA" to cDNA -- (see page 25, line 5 of the specification).

100 MG 11/03/94 5342774

2 145

100.00 CK

RECEIVED  
NOV - 4 94  
OFFICE OF  
THE COMMISSIONER OF  
PATENTS AND TRADEMARKS  
WASHINGTON, D.C.

NOV 28 1994  
May 11 1995  
100.00 CK

Claim 1, line 2: after "MAGE" add -- -1 -- (see examiner's amendment to originally filed claim 12). CIL

Claim 2, line 2: delete "DNA" (see examiner's amendment to originally filed claim 20). K

Claim 4, line 4: change "SEO" to -- SEQ --;  
line 5: after "rejection" add -- antigen -- (see remarks below). CIL

#### REMARKS

All but the amendment to claim 4 were necessitated by errors in the Patent Office printing process. Indeed, it appears that the first error also resulted in printing the patent. Applicants had underlined "SEQ", and the tail of the letter "Q" disappeared in the underlining.


As to the addition of "antigen", applicants inadvertently omitted the term in their amendment under 37 C.F.R. §1.312 submitted on March 26, 1993. Note that there is clear support for this amendment, as per, e.g., the title "tumor rejection antigen precursor", and the use of the phrase in claim 1.

Issuance of a Certificate of Correction is requested.

Respectfully submitted,

FELDE & LYNCH

By

  
Norman D. Hanson  
Reg. No. 30,946

805 Third Avenue  
New York, New York 10022  
(212) 688-9200

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 5,342,774  
DATED : August 30, 1994  
INVENTOR(S) : Thierry Boon et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 5, line 23: change "P515A" to -- P815A --. *P*

Column 10, line 64: change "eDNA" to -- cDNA --. *P*

*col. 57, line 65*

Claim 1, ~~line 2~~: after "MAGE" add -- -1 --. *P*

*col. 57, line 68*

Claim 2, ~~line 2~~: delete "DNA". *P*

*col. 59*

Claim 4, line 4: change "SEO" to -- SEQ --; *P*

line 5: after "rejection" add -- antigen --. *a*